Hannah E. Bergom

Education:
Loyola University - Chicago
Molecular Biology major, Philosophy and Chemistry minors
B.S., 2019

Hannah is currently in the first year of Medical School training and is rotating through labs while preparing to select a thesis advisor.

Publications:

For work prior to the UMN MSTP

Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, Boytim E, Coleman I, Corey E, Plymate SR, Nelson PS, Hwang JH, Drake JM. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts. Mol Cancer Res. 2024 Feb 12. Online ahead of print.

Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, Zorko N, Wang J, Shenderov E, Lobo FP, Caramella-Pereira F, Marchionni L, Drake CG, Lotan T, De Marzo AM, Hwang J, Antonarakis ES. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. NPJ Genom Med. 2024 Jan 22;9(1):7. PMCID: PMC10803790

Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, Boytim E, Coleman I, Corey E, Plymate SR, Nelson PS, Hwang JH, Drake JM. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts. bioRxiv [Preprint]. 2023 Aug 5:2023.08.02.551697. PMCID: PMC10418188

Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. Clin Cancer Res. 2023 Oct 2;29(19):3948-3957. PMCID: PMC10543965

White RE 3rd, Bannister M, Day A, Bergom HE, Tan VM, Hwang J, Dang Nguyen H, Drake JM. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC. Front Oncol. 2023 Jun 30;13:1210487. PMCID: PMC10348659

White RE, Bannister M, Day A, Bergom HE, Tan VM, Hwang J, Nguyen HD, Drake JM. Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer. bioRxiv [Preprint]. 2023 Apr 25:2023.04.22.537922. PMCID: PMC10168214

Hwang J, Shi X, Elliott A, Arnoff TE, McGrath J, Xiu J, Walker P, Bergom HE, Day A, Ahmed S, Tape S, Makovec A, Ali A, Shaker RM, Toye E, Passow R, Lozada JR, Wang J, Lou E, Mouw KW, Carneiro BA, Heath EI, McKay RR, Korn WM, Nabhan C, Ryan CJ, Antonarakis ES. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes. Clin Cancer Res. 2023 Jul 14;29(14):2702-2713. 

Bae SY, Bergom HE, Day A, Greene JT, Sychev ZE, Larson G, Corey E, Plymate SR, Freedman TS, Hwang JH, Drake JM. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer. Front Endocrinol (Lausanne). 2023 Mar 29;14:1093332. PMCID: PMC10090553

Bergom HE, Shabaneh A, Day A, Ali A, Boytim E, Tape S, Lozada JR, Shi X, Kerkvliet CP, McSweeney S, Pitzen SP, Ludwig M, Antonarakis ES, Drake JM, Dehm SM, Ryan CJ, Wang J, Hwang J. ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. Commun Biol. 2023 Apr 14;6(1):417. PMCID: PMC10104859